2016
Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer
Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. Journal Of Clinical Investigation 2016, 126: 4157-4173. PMID: 27721235, PMCID: PMC5096908, DOI: 10.1172/jci87252.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsErbB ReceptorsFemaleHeterograftsHumansIntercellular Adhesion Molecule-1Macrophage-1 AntigenMacrophagesMiceMice, NudeNeoplasm MetastasisNeoplasm ProteinsNeoplasm TransplantationOvarian NeoplasmsSpheroids, CellularVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1ConceptsTumor-associated macrophagesOvarian cancerTranscoelomic metastasisTumor cellsICAM-1Mouse modelEpithelial ovarian cancerOvarian cancer growthOvarian cancer metastasisSpheroid formationOvarian cancer progressionVEGF/VEGFRTumor cell proliferationPharmacological blockadeMetastatic cancerColon cancerCancer growthMetastasisAntibody neutralizationTumor growthCancerClinical pathologyCancer metastasisCancer progressionΑMβ2 integrin
2014
Novel action and mechanism of auranofin in inhibition of vascular endothelial growth factor receptor-3-dependent lymphangiogenesis.
Chen X, Zhou HJ, Huang Q, Lu L, Min W. Novel action and mechanism of auranofin in inhibition of vascular endothelial growth factor receptor-3-dependent lymphangiogenesis. Anti-Cancer Agents In Medicinal Chemistry 2014, 14: 946-54. PMID: 24913775, PMCID: PMC5055472, DOI: 10.2174/1871520614666140610102651.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor receptor 3Lysosome-dependent pathwayProteasomal inhibitor MG132Lysosome inhibitor chloroquineGrowth factor receptor 3Transcription factor NF-κBFactor NF-κBInhibitor MG132EC cell linesReceptor essentialThioredoxin reductaseVivo lymphangiogenesisInhibitor chloroquineNovel targetCancer metastasisEC apoptosisCell linesDose-dependent mannerEC proliferationPotent therapeutic agentMechanism of actionDownregulationLymphangiogenesisRheumatoid arthritisPrimary ECs